https://www.thebodypro.com/category/dolutegravir-tivicay/tag/conference-coverage
Dolutegravir (Tivicay)

Conference Coverage

The Latest

Ricardo Diaz

Researcher Behind "Brazil Patient," the Latest HIV Remission Case, Explains How It Happened

The international news story that broke at AIDS 2020, explained by the lead researcher.

By Terri Wilder, M.S.W.
Ricardo Diaz, M.D. (top left) shares findings regarding a potential new HIV remission case in a virtual press conference during the 23rd International AIDS Conference on July 7, 2020.

HIV Clinical Research Highlights From AIDS 2020, the 23rd International AIDS Conference

COVID-19 or no, there was still plenty to learn at this year's virtual conference, including for U.S. clinicians seeking to improve the care and treatment they provide to their patients living with HIV.

By Myles Helfand
pregnant belly

Tempering Previous Concerns, Study Finds Dolutegravir Safest HIV Treatment During Pregnancy

New data shows the drug is not more likely to cause birth defects.

By Sony Salzman
pill bottles on page full of data

Two-Drug HIV Regimen Works Well Except in People With Low CD4 Count, Study Finds

The combination of dolutegravir and lamivudine is effective for treatment-naive patients regardless of age, gender, or race, according to a new subgroup analysis of the GEMINI clinical studies.

By Sony Salzman
Pair of female feet on a bathroom scale

One Class of HIV Drugs Is Associated With Weight Gain. What's the Latest?

The question of whether INSTIs cause weight gain continues to be debated. This story draws together some research on which drugs are associated with weight gain or other metabolic changes.

By Sony Salzman
Fernanda Fernandes Fonseca and Meg Doherty at an IAS 2019 press conference

World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy

New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.

By Sony Salzman
Mexico City's Downtown At Twilight

IAS 2019: What to Expect in HIV Science

Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.

By Sony Salzman
Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows Img

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman
Dolutegravir Monotherapy: Still No Longer Recommended in Either Research or Clinical Practice Img

Dolutegravir Monotherapy: Still No Longer Recommended in Either Research or Clinical Practice

Although treatment guidelines since 2016 recommend against further research into the use of dolutegravir monotherapy, it was disconcerting to have two oral presentations at AIDS 2018 reporting studies that still continued after the 2016 recommendatio...

By Simon Collins for HIV i-Base
Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin Img

Twice-Daily Dolutegravir Is Effective and Tolerable With Rifampicin

24-week interim results from the INSPIRING study presented at CROI 2018 show that dolutegravir 50 mg twice daily is effective and well-tolerated in adults with HIV/TB receiving rifampicin-based TB treatment.

By Polly Clayden for HIV i-Base